BIO VIEW (Israel) Analysis

The current indifference towards the small price fluctuations of BIO VIEW could raise concerns from investors as the firm is trading at a share price of 0.0 on very low momentum in volume. The company management teams did not add any value to BIO VIEW investors in September. However, most investors can still diversify their portfolios with BIO VIEW to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently very low. The very small Stock volatility is a good signal to investors with longer-term investment horizons.
Check out Trending Equities.
  
The BIO VIEW stock analysis report makes it easy to digest most publicly released information about BIO VIEW and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. BIO VIEW Stock analysis module also helps to analyze the BIO VIEW price relationship with some important fundamental indicators such as market cap and management efficiency.

BIO VIEW Stock Analysis Notes

The company recorded a loss per share of 0.1. BIO VIEW last dividend was issued on the 22nd of March 2017. BioView Ltd. develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company was founded in 2000 and is headquartered in Rehovot, Israel. BIO VIEW is traded on Tel Aviv Stock Exchange in Israel. For more info on BIO VIEW please contact Yuval Harari at 972 73 227 1025 or go to http://www.bioview.com.

BIO VIEW Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. BIO VIEW's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding BIO VIEW or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
BIO VIEW is not yet fully synchronised with the market data
BIO VIEW has some characteristics of a very speculative penny stock
BIO VIEW has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 27.22 M. Net Loss for the year was (1.37 M) with profit before overhead, payroll, taxes, and interest of 14.76 M.

BIO VIEW Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 3.73 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BIO VIEW's market, we take the total number of its shares issued and multiply it by BIO VIEW's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

BIO VIEW Profitablity

BIO VIEW's profitability indicators refer to fundamental financial ratios that showcase BIO VIEW's ability to generate income relative to its revenue or operating costs. If, let's say, BIO VIEW is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, BIO VIEW's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of BIO VIEW's profitability requires more research than a typical breakdown of BIO VIEW's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (5.03) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (5.93) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.06.

Management Efficiency

The entity has return on total asset (ROA) of (3.69) % which means that it has lost $3.69 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (6.08) %, meaning that it generated substantial loss on money invested by shareholders. BIO VIEW management efficiency ratios could be used to measure how well bio view manages its routine affairs as well as how well it operates its assets and liabilities.

BIO VIEW Technical and Predictive Indicators

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding BIO VIEW to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Cryptocurrency Center Now

   

Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
All  Next Launch Module
Check out Trending Equities. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Other Tools for BIO VIEW Stock

When running BIO VIEW price analysis, check to measure BIO VIEW's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BIO VIEW is operating at the current time. Most of BIO VIEW's value examination focuses on studying past and present price action to predict the probability of BIO VIEW's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move BIO VIEW's price. Additionally, you may evaluate how the addition of BIO VIEW to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
CEO Directory
Screen CEOs from public companies around the world
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go